http://www.compact-research.org/) .
Additionally, for the past 4 years, Steve has been responsible for helping GSK Programme teams explore “Where does my drug go and what does it do when it gets there?” using a range of Bioimaging methodologies.
Finally, after joining the GSK Bioimaging team as a Director in 2015, Steve is actively involved in facilitating the interaction between academia , biotech and large industry partners in the Bioimaging Expertise Network (BEN). Steve has recently succeded Zane Arp as Director for GSK’s Center for Optical Molecular Imaging a joint venture with the University of Illinois at Urbana-Champaign.
Steve is a Fellow of the Royal Society of Biology, The Drug Metabolism Discussion Group and a Senior Fellow in the GSK Fellows programme.
">
- Steve was awarded a BSc in Biochemistry and a PhD in Molecular Toxicology from Surrey University before joining Glaxo Group Research as a Post-Doctoral Fellow in 1993. Following the formation of GSK in 2001, Steve managed a team determining the drug-drug interaction liabilities while developing ADME strategies for the emerging GSK antibody portfolio.
- In 2010, Steve led a cross divisional team charged with understanding and overcoming the delivery issues inherent in GSK’s diverse oligonucleotide portfolio while helping to develop these molecules from early discovery to file. In 2011 Steve initiated a project that has grown into the active IMI academic/Industry COMPACT collaboration (http://www.compact-research.org/) .
- Additionally, for the past 4 years, Steve has been responsible for helping GSK Programme teams explore “Where does my drug go and what does it do when it gets there?” using a range of Bioimaging methodologies.
- Finally, after joining the GSK Bioimaging team as a Director in 2015, Steve is actively involved in facilitating the interaction between academia , biotech and large industry partners in the Bioimaging Expertise Network (BEN). Steve has recently succeded Zane Arp as Director for GSK’s Center for Optical Molecular Imaging a joint venture with the University of Illinois at Urbana-Champaign.
- Steve is a Fellow of the Royal Society of Biology, The Drug Metabolism Discussion Group and a Senior Fellow in the GSK Fellows programme.